Abstract. An open-label prospective cross-over trial was performed to compare the efficacy and adverse effects of nateglinide with those of voglibose on Japanese early type 2 diabetes (who were oral hypoglycemic agent naïve and whose HbA 1C levels were between 7.0 and 7.9% before treatment). Fourteen patients received 270 mg/day of nateglinide and 15 patients received 0.6 mg/day of voglibose. After 12 weeks of either therapy, the drugs were switched and treatment was continued for another 12 weeks. After 3-month treatment with each drug, HbA 1C value decreased significantly (baseline HbA 1C 7.24 ± 0.42%, 6.70 ± 0.47% with nateglinide: p<0.01, 6.93 ± 0.62% with voglibose: p<0.05) but the difference in the effect between nateglinide and voglibose was not significant (p = 0.121). Symptoms related to hypoglycemia (e.g., increased appetite, palpitation, sweating, tremor) were scarcely observed with either voglibose or nateglinide treatments. Abdominal fullness/borborygmi was frequently reported, with variable severity, by patients on voglibose but this was absent or mild in those on nateglinide. After completion of both arms of the study, more patients favored nateglinide than voglibose. Our results suggest that nateglinide is an effective and safe drug in the treatment of early type 2 diabetes, similar to voglibose.
THE earliest determinant of progression to type 2 diabetes in Japanese population is the loss of early insulin secretion, a defect that results in postprandial hyperglycemia [1] [2] [3] [4] [5] [6] [7] [8] . Postprandial hyperglycemia observed in impaired glucose tolerance may be a prospective determinant of cardiovascular disease [9] [10] [11] and the efficacy of intervention to treat this abnormality has been reported or is currently under investigation [12, 13] . The above background suggests that we have to treat patients with early type 2 diabetes more intensively and to continue to search for effective and acceptable oral hyperglycemic agents for early type 2 diabetes.
Nateglinide is a novel highly physiologic, mealtime glucose regulator recently approved for the treatment of type 2 diabetes [14, 15] . Nateglinide selectively enhances early meal-induced insulin secretion and thus improves postprandial hyperglycemia. The major adverse effect of nateglinide is hypoglycemia, and thus its use has been limited to patients with severe type 2 diabetes on a-glucosidase inhibitors rather than to those with early type 2 diabetes.
The aim of the present cross-over study was to compare the effects and safety of nateglinide on early type 2 diabetes with those of voglibose, an a-glucosidase inhibitor that is mainly prescribed in Japan for the treatment of early type 2 diabetes population.
Subjects and Methods
Twenty-nine type 2 diabetes outpatients under diet and exercise therapy were randomly selected and enrolled in this study. Patients eligible for enrollment were naïve adults who were on oral hypoglycemic agents and whose HbA 1C had been between 7.0 to 7.9% for more than 3 months before the start of this study. At the time of enrollment in the study, patients were divided randomly into two groups. The first group was started on 270 mg/day of nateglinide (90 mg before each meal) (n = 15) while the second group was started on 0.6 mg/day of voglibose (0.2 mg before each meal) (n = 14). A fasting blood sample was collected from each patient at baseline (before commencement of therapy). The backgrounds and characteristics of the patients of both groups are shown in Table 1 . They were treated for 12 weeks and subsequently switched to the opposite drugs (nateglinide to voglibose (N-V group) and voglibose to nateglinide (V-N group)) for 12 weeks after collecting more blood samples. A questionnaire was provided to each patient after the completion of each treatment protocol on complications encountered during the treatment, e.g., hypoglycemic symptoms, change of appetite, and abdominal fullness or borborygmi. After completion of both treatments, another questionnaire was provided to each patient requesting their choice of therapy from the two test antidiabetic agents. During this study, none of the patients was prescribed other hypoglycemic agents. Moreover, none was on anti-hypertensive, hypolipidemic, or antiplatelet drugs during this study. All patients gave informed consent to participation in this open-label prospective cross-over study.
Laboratory data were compared between the two groups using Student's paired t-test. Fisher's exact test was used for the frequency of hypoglycemia-related symptoms. Wilcoxon test was used for the degree of gastrointestinal symptoms and change of appetite. All laboratory results are expressed as mean ± SD.
Results
The demographic characteristics and baseline data of patients of the two groups are summarized in Table 1 . The table does not show the data of 4 patients who were originally entered in this study but later withdrew due to severe gastrointestinal side effects induced by voglibose. All the subjects who completed the study took their drugs almost exactly as specified.
The baseline laboratory data are also shown in Table  1 for both groups. Age, gender, duration of diabetes, blood pressure, body mass index, HbA 1C , liver function (GOT, GPT, g-GTP) and lipid profile (totalcholesterol, triglyceride, HDL-cholesterol) at baseline were not significantly different between the two groups.
The parameters used for evaluation of each drug are summarized in Table 2 . The primary parameter of Comparison of other biochemical data obtained before and after each drug also showed no significant difference (data not shown). Based on these results, we concluded that both nateglinide and voglibose were suitable and effective drugs for treatment of early type 2 diabetes.
The major concern related to voglibose treatment is abdominal fullness/borborygmi, while that related to nateglinide is hypoglycemia. In this study, all patients were asked to report the severity of gastrointestinal symptoms including abdominal fullness and borborygmi at each follow-up visit. Table 3 lists the severity divided into 5 grades. During voglibose treatment, 21 of 29 patients reported mild/often to severe/often gastrointestinal symptoms, while only 5 of those on nateglinide reported this symptom.
Patients also were asked about hypoglycemic symptoms at each follow-up visit. These symptoms included increased appetite, sweating, shivering, palpitation, dizziness, and unreasonable discomfort. Increase of appetite and other symptoms are indicated separately in Table 3 . During nateglinide treatment, 6 of 29 patients reported mild increase of appetite while during voglibose 7 did. Two patients on nateglinide and one on voglibose reported reduction of appetite. On the other hand, 1 of 29 patients on nateglinide complained of hypoglycemic symptoms, while 5 on voglibose reported these symptoms. Five patients on voglibose complained of hypoglycemic symptoms, but those complaints were actually related to gastrointestinal adverse effects after detailed inquiry. Neither drug induced severe hypoglycemia when glycosylated hemoglobin level of the patients was >7.0%.
After completion of both treatments, 13 patients (45%) favored nateglinide and 12 had no preference, and 4 selected voglibose. These results suggest that nateglinide is as effective as voglinibose for glycemic control in patients with early type 2 diabetes though it seems to be the more acceptable oral hypoglycemic agent taking into consideration its gastrointestinal adverse effects.
Discussion
Recent studies indicated that fasting glucose concentrations alone do not identify individuals at increased risk of death associated with hyperglycemia and that mealtime glycemia significantly contributes to overall glycemic control and coronary artery disease mortality [9] [10] [11] . In this regard, even subjects with impaired glucose tolerance are also at risk of death similar to type 2 diabetes patients. At present, various therapies are available for direct improvement of postprandial hyperglycemia. One group is a-glucosidase inhibitors, while another group is the "glinides", representing rapid insulin secretagogues. Acarbose, miglitol and voglibose act by competitively inhibiting a-glucosidases, a group of key intestinal enzymes involved in the diges- tion of carbohydrates. They reduce both postprandial hyperglycemia and hyperinsulinemia, and thereby may improve sensitivity to insulin and release the stress on pancreatic b-cells. These compounds do not induce hypoglycemia and have a good safety profile [16] ; therefore they are widely prescribed for early type 2 diabetes patients in Japanese population. However, the gastrointestinal adverse effects of these drugs may limit long-term compliance to therapy. In this study, nateglinide, one of the "glinides" compounds, selectively enhanced early meal-induced insulin secretion and thus improved mealtime glucose control. Consistent with the more physiological nature of nateglinide, the overall insulin exposure is relatively lower than that produced by sulfonylurea medication in type 2 diabetes [14, 15] . We have previously described that nateglinide improved glycemic response after oral glucose load in obese individuals with impaired glucose tolerance or early type 2 diabetes by improvement of early phase insulin secretion without increasing the total amount of insulin (i.e., area under the curve) [17, 18] .
In the present study, we showed that administration of nateglinide and voglibose resulted in almost similar and significant improvement in early type 2 diabetic patients whose glycosylated hemoglobin level ranged between 7.0 and 7.9% (nateglinide vs. voglibose, V-N group 6.77 ± 0.51% vs. 6.97 ± 0.64%, N-V group 6.62 ± 0.42% vs. 6.88 ± 0.64%). Comparison of the two drugs showed that voglibose use tended to reduce body weight compared with nateglinide but the difference was not statistically significant. The effects of voglibose on body weight has been obscure but it has been reported that this drug effectively reduces body weight [19] or abdominal visceral adipose tissue area in newly diagnosed type 2 diabetes [20] .
Symptoms related to hypoglycemia (increased appetite, palpitation, sweating, or tremor) were scarcely observed with nateglinide treatment as well as voglibose. We compared previously the effects of a small dose of gliclazide (20 mg) with those of nateglinide (270 mg), and reported that the hypoglycemic effects of gliclazide tended to be stronger though the drug elicited more frequent hypoglycemic episodes than nateglinide [21] . In another study, the hypoglycemic effect of nateglinide appeared immediately and did not last more than 6 hours even when administered at a single high dose (3,420 mg) [22] .
On the other hand, abdominal fullness/borborygmi was frequently reported in patients treated with voglibose though it varied in severity, while none or milder complaint was reported by those of the nateglinide group. The reported frequency and severity of gastrointestinal side effects of a-glucosidase inhibitors varies in different studies. Scorpiglione et al. [23] reported that ~33% of their type 2 diabetic patients could not continue on acarbose for the whole study period mainly due to gastrointestinal side effects. In a recent prevention study of a wide spectrum of the disease from impaired glucose tolerance to type 2 diabetes using acarbose, 13% of the acarbose group prematurely discontinued the therapy due to gastrointestinal symptoms, compared with 3% of the placebo group [24] . In this regard, adverse drug events were reported to be more common in acarbose-treated patients than those on voglibose [16] . The reason for the preference of nateglinide as the choice drug in our study may depend on the frequency or severity of gastrointestinal adverse effects. The latter may directly influence the compliance of these drugs.
In conclusion, our data indicate that nateglinide is an effective and safe drug for the treatment of early type 2 diabetes, similar to voglibose. The drug used for treatment of postprandial hyperglycemia should be selected for each subject taking into consideration its efficacy and adverse effects.
